Warfarin dosing test
This article was originally published in The Gray Sheet
Executive Summary
Kimball Genetics joins the small number of labs performing pharmacogenetic tests for warfarin therapy with the launch of its Warfarin DoseAdvise June 5. The test, performed at Kimball's CLIA-certified lab in Denver, analyzes genes in blood or cheek cell samples to inform dosing of the common blood thinner. According to Kimball CEO Annette Taylor, FDA plans to revise warfarin product labeling to advocate genetic testing. Other labs offering warfarin dosing tests include Clinical Data (PGxPredict). Third Wave, which sells reagents for warfarin tests, is developing the Invader warfarin in vitro diagnostic (1"The Gray Sheet" March 6, 2006, p. 12)...
You may also be interested in...
Third Wave, Now An IVD Company, Is Banking On Personalized Medicine
Third Wave Technologies is banking on its emerging portfolio of in vitro diagnostic products designed to tailor drug therapy to recover from substantial revenue losses in its research products business
Belgium Aims To Drive Biologic Competition Through Tendering
New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.
EU Bodies Agree On Ways To Future-Proof EMA Funding System
EU ministers say that implementing an appropriate fee structure that is more in line with actual costs will promote innovation in the pharmaceutical sector while ensuring “fair access” to safe and effective medicines for patients.